Premium
The rationale of the myo‐inositol and D‐chiro‐inositol combined treatment for polycystic ovary syndrome
Author(s) -
Dinicola Simona,
Chiu Tony T. Y.,
Unfer Vittorio,
Carlomagno Gianfranco,
Bizzarri Mariano
Publication year - 2014
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.362
Subject(s) - anovulation , polycystic ovary , inositol , insulin resistance , endocrinology , medicine , infertility , endocrine system , ovary , insulin , biology , pregnancy , hormone , receptor , genetics
PCOS is one of the most common endocrine disorders affecting women and it is characterized by a combination of hyper‐androgenism, chronic anovulation, and insulin resistance. While a significant progress has recently been made in the diagnosis for PCOS, the optimal infertility treatment remains to be determined. Two inositol isomers, myo‐inositol (MI) and D ‐chiro‐inositol (DCI) have been proven to be effective in PCOS treatment, by improving insulin resistance, serum androgen levels and many features of the metabolic syndrome. However, DCI alone, mostly when it is administered at high dosage, negatively affects oocyte quality, whereas the association MI/DCI, in a combination reproducing the plasma physiological ratio (40:1), represents a promising alternative in achieving better clinical results, by counteracting PCOS at both systemic and ovary level.